ABSTRACT
To explore the therapeutic effect and safety of target-dose metoprolol in treating chronic heart failure [CHF] patients complicated with diabetes mellitus [DM]. One hundred and fifty-four elderly patients were randomly divided into an observation group and a control group [n=77], which were treated with target-dose metoprolol and conventional therapy, and routinely treated respectively. The New York Heart Association [NYHA] classification, left ventricular end-systolic diameter [LVESD], left ventricular end-diastolic diameter [LVEDD], left ventricular ejection fraction [LVEF], 6-min walking distance and medication safety of the two groups were compared. Compared with the results before treatment, the NYHA classification, LVESD, LVEDD, LVEF and 6-minutes walking distance of both groups were significantly improved [P < 0.05], with significantly better results in the observation group than those in the control group after treatment [P < 0.05]. In the 6 months of follow-up, the incidence of cardiac events in the observation group [3.90%] was significantly lower than that of the control group [14.29%] [P < 0.05]. The levels of average fasting blood sugar and glycosylated hemoglobin in the groups showed no significant differences [P > 0.05]. Treating CHF patients complicated with DM with target-dose metoprolol can obviously boost the cardiac function and exercise tolerance, leading to satisfactory clinical therapeutic effect, high security and moderate tolerance
ABSTRACT
OBJECTIVE To evaluate the availability and safety of a new carbapenem meropenem.METHODS The randomized study was conducted in 60 patients with respiratory tract infections.They were divided into two groups:meropenem or imipenem/cilastatin.RESULTS The cure rate,effective rate and bacterial clearance rate for meropenem were 80.0%,93.3%,92.3%,respectively and for those of imipenem/cilastatin were 76.7%,90.0% and 91.3%,respectively.The rate of adverse reactions for both meropenem/cilastatin was 3.3%.CONCLUSION Meropenem appeared to be a highly effective and safe agent in treatment of respiratory tract infections.Its efficacy and safety are similar to that of imipenem/cilastatin.